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Background and Aim: To analyze the influence on weight gain of infants exposed to two dosage regimens
of oral caffeine citrate (CC) for apnea of prematurity.
Methods: Retrospective descriptive observational study of an eligible very low birth weight cohort over
a 15-year period in an Irish University hospital. Data were analyzed between two distinct postnatal ages:
14–28 and 29–56 days.
Results:During the 15-year study, 457 infants were prescribed caffeine. Among the 14–28-day group, after
applying exclusion criteria, 418 infants qualified. Two hundred forty-eight infants received 5mg/(kg$day)
and 170 received 10mg/(kg$day) of CC. Among the 29–56-day group, 362 infants were identified and after
applying exclusions, 332 fulfilled entry criteria [214 on 5mg/(kg$day) and 118 on 10mg/(kg$day) regi-
men]. Baseline characteristics of infants were comparable between groups without statistically significant
differences. Mean daily weight gain (MDWG) in grams from day 14 to 28 showed a higher rate of increase
for the 5mg/(kg$day) group compared with the 10mg/(kg$day) group (17.2– 12 g vs. 13.0 – 10.2 g
[p = 0.04]). From day 29 to 56, also MDWG was higher among infants on 5mg/(kg$day) of CC compared
with 10mg/(kg$day) group (15.6– 10.8 g vs. 10.2– 9.8 g [p= 0.011]).
Conclusion:While a variety of measures are optimized to promote postnatal weight gain of premature in-
fants close to an ideal intrauterine growth curve, not paying sufficient attention to one of the most widely
used catabolic agents in neonatology is questionable and warrants vigilance. Additional nutritional mea-
sures could be offered to those with prolonged caffeine exposure.
Keywords: neonatal intensive care unit, caffeine citrate, apnea of prematurity, very low birth weight in-
fants, methylxanthines, neonatal nutrition
Introduction
Apnea of prematurity (AOP) is defined as thecessation of spontaneous breathing by a premature
infant lasting for more than 20 seconds and/or accompa-
nied by hypoxia or bradycardia.1 Caffeine citrate (CC)
is the commonest methylxanthine universally used in
the management of AOP, which occurs in about 85% of in-
fants born at less than 34 weeks of gestation.2 It has been
the mainstay of pharmacologic treatment of apnea of AOP
for over 30 years and is often prescribed for very pre-
mature infants until they reach a postmenstrual age of
32–34 weeks.3,4 Caffeine therapy for AOP has also been
shown to reduce the rate of bronchopulmonary dysplasia
and improves the rate of survival of very low birth weight
(VLBW) infants without neurodevelopmental disability
at 18–21 months.5,6 Caffeine is one of the most pre-
scribed drugs in the current neonatal practice. Its efficacy,
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tolerability, wide therapeutic index, and safety margin
have made it the drug of choice for AOP and is often
used cumulatively for many weeks with potential cata-
bolic effects that could impact on the initial weight gain
of this vulnerable population.7
Effects of caffeine intake during pregnancy were ana-
lyzed by the CARE Study Group and highlighted the asso-
ciation of fetal growth restriction to caffeine consumption
during pregnancy.8 Their observation, along with similar
findings from previous studies, suggests that fetal growth
restriction secondary to high-dose maternal caffeine expo-
sure is consistent across all trimesters.8,9 An incremental in-
take of caffeine during pregnancy was reported with LBW
in 7% and small for gestational age (SGA) in 10%.10 Even
though 18–21-month follow-up of caffeine-exposed infants
for the treatment of AOP did not show reduction in weight
or head circumference, somatic effect of dose- and
duration-specific exposure during the neonatal period
is not ascertained.
Caffeine readily crosses the blood/brain barrier and is a
central nervous system stimulant. The principalmode of ac-
tion is as an antagonist of adenosine receptors, which are G
protein-coupled receptors.11,12 Caffeine is a competitive
inhibitor of cAMP-phosphodiesterase enzyme, which con-
verts cyclic AMP to its noncyclic form, thus allowing
cAMP to build up in cells. Cyclic AMP participates in
the activation of protein kinase A to begin the phosphory-
lation of specific enzymes used in the glucose synthesis.
By blocking its removal, caffeine intensifies and prolongs
the effects of epinephrine and epinephrine-like drugs.11,13
Cyclic AMP also directly increases heart rate, and caffeine
increases the metabolic rate and oxygen consumption.14
Methylxanthines increase energy expenditure indepen-
dently of physical activity and also enhance carbohydrate
utilization in the infant.9 Studies have suggested that
caffeine also reduced splanchnic blood flow in the neo-
natal gut.15 Caffeine is a diuretic and is based on the dif-
ferential expression of adenosine A1 receptors. Caffeine
increases glomerular filtration (causing diuresis) through
action on afferent arteriole and reduces sodium reab-
sorption (causing natriuresis) at the level of proximal
tubules.16–18 In baboon models with prematurity and
respiratory distress, caffeine was associated with a dou-
bling of urine output.19 The abovementioned mechanisms
of action cumulatively contribute to the catabolic effects
of caffeine during the neonatal period and thus negatively
influence the weight gain.
While caffeine has respiratory benefits for preterm in-
fants, it may have adverse molecular and cellular effects
on the developing brain.20,21 Half-life of caffeine varies
widely among infants based on their liver function status,
exposure to certain concurrent medications, and the level
of hepatic enzymes needed for metabolism. Among
healthy adults, caffeine’s half-life is *4.9 hours and in
pregnant women 9–11 hours.8 Among infants and chil-
dren, half-life is longer and for newborn infants could
be up to 30 hours and as per a more recent study, the
mean caffeine half-life was 87 – 25 hours at 35 – 1
week postmenstrual age.22
Caffeine is metabolized in the liver by the cytochrome
P450 oxidase enzyme system (specifically the 1A2 isoen-
zyme) into three forms of dimethylxanthines, each with
their own effects on the human body: (1) paraxanthine,
(2) Theobromine, and (3) theophylline. They are further
metabolized and excreted in urine.11 Paraxanthine in-
creases lipolysis, which releases glycerol and fatty acids
into blood to be used as fuel by the muscles. Theobromine
is a vasodilator that increases the amount of nutrient flow to
the brain and muscles. Theophylline acts as a smooth mus-
cle relaxant, however, acts also as a chronotrope and ino-
trope, increasing heart rate and contractility.13
Caffeine through its effect on metabolic rate, diuretic
action, hyperglycemic property, and catabolic tendency
could influence the short-term growth, especially consid-
ering the current practice of prolonged postnatal caffeine
therapy for AOP.8,10,23 A recent study has suggested an
osteopenic effect of caffeine on premature infants and
perhaps contributes adversely to the bone growth of ex-
tremely low birth weight (ELBW) population as well.24
We undertook this retrospective descriptive cohort study
with an objective to determine the effects on mean daily
weight gain (MDWG) of ELBW and VLBW infants trea-
ted with two different oral dosage schedules of CC for the
treatment of AOP [5mg/(kg$day) vs. 10mg/(kg$day)].
Aims
To recognize and analyze the influence on postnatal
weight gain of ELBW (below 1000 g birth weight) and
VLBW (below 1500 g birth weight) infants exposed to
two dosage regimens of oral CC for the management of
AOP. To highlight the importance of growth monitoring
and nutritional supplementation of premature infants ex-
posed to prolonged duration of oral CC during a vulner-
able period of critical somatic growth.
Methods
Patient population
This study was carried out in the NICU of University
Maternity Hospital Limerick (UMHL), Ireland, between
January 2002 and December 2016. Our maternity hospi-
tal has an in-birth rate approximating 5000 per year from
a fairly fixed Caucasian population (ethnic minorities ac-
counting for <10% of antenatal booking) with an antena-
tal steroid uptake of 91% for the eligible population. Our
expressed breast milk exposure (mother’s own milk or
donor breast milk) for the VLBW infants was 40% in
2005, 80% in 2012, and 91% in 2016. For the ELBW
infants, breast milk use steadily increased from 20% in
2005 to 90% in 2012 and through a quality improvement
project reached 100% from 2014 to 2016.21 Inclusion cri-
teria were (1) ELBW and VLBW infants born in our
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hospital during the study period with birth weight of
<1500 g and gestational age of 23–30 weeks, and (2) in-
fants requiring treatment with oral CC for AOP. Exclusion
criteria were (1) infants born with major congenital anom-
alies, (2) infants concurrently receiving other medicines
that could influence weight gain such as diuretics, ibupro-
fen, indomethacin, or postnatal corticosteroids, (3) infants
transferred in/out of the unit from/to other neonatal centers,
(4) infants with blood culture-proven sepsis during the
course of oral caffeine treatment, (5) grade 3/4 intraventric-
ular hemorrhage (IVH), (6) infants on fluid restriction, (7)
infants who have received middle of the dosage range of
7–8mg/(kg$day) of CC from the treating team, (8) infants
with necrotizing enterocolitis (NEC) with modified Bell’s
stage 2b and above,25 and (9) infants while receiving intra-
venous caffeine. With our unit’s enhanced breast milk up-
take for the prevention of NEC, there was a significant
reduction of confirmed NEC in the second half of the
study period (12 in 2002–2008 and 4 in 2009–2016 period).
Intravenous caffeine was the choice for the first few days
and was converted to oral route subsequently when tolerat-
ing sufficient nasogastric feeds. Infants who were initially
on intravenous CC and subsequently converted to oral caf-
feine were included in the study. Those who did not ini-
tially receive intravenous caffeine, however, subsequently
required oral caffeine during days 14–28 or 29–56 days,
were also included in the study.
We did not exclude infants based on maternal caffeine/
tobacco exposure and no data were collected in this
regard. Infants were not excluded based on enteral versus
parenteral route of nutrition, type of enteral feeding, or
caloric/protein concentration of the feeds used. During
the study period, powdered cow’s milk-based milk forti-
fier was used when infants reached 100mL/kg of breast
milk intake. We acknowledge that the use of breast
milk fortifier or the universal use of donor breast milk
was not established in our unit during the 2002–2010 pe-
riod. Contribution by SGA within the study population
was not separately analyzed.
Data sources
Study variables were obtained from the manually en-
tered neonatal drug kardex (drug prescription charts), se-
rially recorded weight chart from the nursing notes,
demographic characteristics collected from the patient
admission record in NICU, annually collated and submit-
ted data toward the VON (Vermont Oxford Network) in-
ternational benchmarking of all infants below 1500 g
birth weight, hospital inpatient enquiry data, and the
computerized patient admission system.
Intervention and outcome measurement
Infants during the study period were treated with two
different dosing regimens: (1) 5mg/(kg$day) dose of
CC equivalent to 2.5mg/(kg$day) caffeine base and (2)
10mg/(kg$day) dose of CC equivalent to 5mg/(kg$day)
caffeine base. This resulted from the local guidelines
based on published dosage schedules that recommended
5–10mg/(kg$day) of CC as the maintenance dose after
the initial loading of 20mg/kg.5,6,10 The decisions on
dose and duration of treatment were made entirely by the
neonatal teams responsible for the care of the infants.
There were no significant changes in our senior medical
faculty during the study period. Our unit used oral CC
50mg/5mL (equivalent to caffeine base of 25mg/5mL),
ML number 0427-01, Rosemount Pharmaceuticals Ltd.
(Leeds, United Kingdom), during the first half of study
and a specifically licensed product for neonatal use
(Peyona, CC 20mg/mL oral solution by Chiesi Ltd.) dur-
ing the second half.
Weight gain/loss in all infants admitted to the neonatal
unit, including those enrolled in our study, was routinely
measured three times weekly from birth to discharge by
experienced neonatal nursing staff. More frequent weight
checks were done if clinically indicated. For the purposes
of this study, MDWG in g/(kg$day) was calculated for el-
igible infants between two specific time periods: (1) day
of life 14–28 and (2) day of life 29–56. We chose to col-
lect data on recorded MDWG only from day 14 of life, as
many of the ELBW and VLBW infants often physiolog-
ically lose weight during the first week after birth (mean
weight loss of 14% in the first 6 days) and often start
regaining weight only from the second week of postnatal
life.26 Analysis of other adverse effects of caffeine ther-
apy or measuring serum levels of caffeine was not con-
ducted as part of our study.27
Outcome analysis
For purposes of analysis, we also recorded the patient
characteristics—gestation at birth, birth weight, duration
and mode of ventilatory support, duration and dose of
supplemental oxygen, and the kcal/kg of caloric nutri-
tional intake and g/kg of nutritional protein intake (via
enteral or parenteral nutrition). We tabulated our results
using Microsoft Excel and statistical analysis was done
with SPSS version 23 (SPSS, Chicago, IL).
Ethical consideration
Study was approved by the University Maternity Hos-
pital Audit Committee. Standard sets of clinical data
from infants were included in our study, were collected
anonymously, and infants were not exposed to placebo,
novel intervention, or new dosage regimen.
Results
Study infants
During the 15-year study period, a total of 457 ELBW
and VLBW infants were exposed to CC. Among the
14–28-day group, after applying the exclusion criteria,
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418 qualified for the analysis. Among them, 248 received
5mg/(kg$day) and 170 received 10mg/(kg$day) of CC.
Among the 29–56-day group, a total of 362 infants
were identified and after applying the exclusions, 332 pa-
tients who fulfilled the entry criteria were included [214
on the 5mg/(kg$day) of CC regimen and 118 on the
10mg/(kg$day) regimen]. Baseline characteristics of
these infants are summarized in Table 1 and are compa-
rable without statistically significant differences. Table 2
summarizes the neonatal population characteristics over
15 years.
Mean daily weight gain
When MDWG was calculated for the study population
from day of life 14 to 28, we found a higher rate of increase
for the 5mg/(kg$day) group compared with the 10mg/
(kg$day) group (17.2– 12 vs. 13.0– 10.2 [p= 0.04]). A
similar MDWG pattern was observed for the study popula-
tion from day of life 29 to 56 as well. The rate of increase
in MDWG was higher in the infants on the lower dose/kg
of CC, that is, the 5mg/(kg$day) cohort compared with
the 10mg/(kg$day) cohort (15.6 – 10.8 vs. 10.2 – 9.8
[p = 0.011]). Our findings are summarized in Table 3.
Our unit only had a relatively small number of infants in
the gestation and birth weight category who did not receive
CC treatment during theirNICUstay. This perhaps reflects a
possible nonrestricted caffeine use in our unit or could be
a manifestation of comfort of modern neonatal units to
have a relatively liberal caffeine commencement and main-
tenance policy. Our VLBW and ELBW infants who were
never exposed to postnatal caffeine were 157 and after
using the exclusion criteria, only 92 infants qualified and
75 (81.5%) were ‡1000g and ‡30 weeks of gestation at
birth. Considering the limited number of infants in this sub-
group, further analysis was not done as the derivation of
clinical significance from our findingsmight not be prudent.
Table 1. Baseline Characteristics of Premature Infants Exposed to Caffeine Citrate
at Two Different Doses
Days of treatment 14–28 days p 29–56 days p
Dose of CC, mg/(kg$day) 5 10 5 10
n 248 170 214 118
Birth weight, g 1074– 418 1002– 426 0.318 998– 480 1010 – 442 0.229
SIMV/PTV/HFOV, days 24 – 18 22 – 14 0.476 20– 17 22 – 14 0.440
NCPAP/HFT, days 28 – 16 32 – 12 0.270 30– 18 34 – 14 0.440
Kcal/kg 116 – 18 120– 26 0.158 118– 22 122 – 24 0.153
Supplemental oxygen, days 22 – 12 18 – 10 0.157 38– 20 36 – 13 0.610
Variables are given as mean – standard deviation.
CC, caffeine citrate; HFOV, high-frequency oscillatory ventilation; HFT, high-flow humidified oxygen therapy; NCPAP, nasal con-
tinuous positive airway pressure; PTV, patient-triggered ventilation; SIMV, synchronized intermittent mandatory ventilation.
Table 2. Perinatal and Neonatal Population Characteristics Over 15 Years and the Trend in the Use
of Caffeine Citrate Among Extremely Low Birth Weight and Very Low Birth Weight Infants
Year
Number of ELBW
and VLBW
infants exposed
to caffeine/year Live births
Neonatal
admissions <1000 g 1000–1500 g Still births
2002 19 4371 757 6 25 26
2003 31 4514 693 16 26 28
2004 30 4418 723 20 17 27
2005 29 4411 688 10 31 28
2006 36 4692 891 16 31 16
2007 34 5153 893 12 43 22
2008 28 5443 995 12 26 30
2009 36 5432 1087 13 31 24
2010 38 5233 929 17 35 32
2011 22 5137 983 11 16 23
2012 34 4905 906 17 26 22
2013 30 4594 758 13 29 18
2014 29 4522 662 13 23 17
2015 33 4690 761 12 33 24
2016 28 4473 857 10 24 16
Total 457 71,988 12,583 198 416 353
University Maternity Hospital Limerick (UMHL), Ireland 2002–2016.
ELBW, extremely low birth weight; VLBW, very low birth weight.
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Discussion
Our observation suggests a clinically and statistically
significant reduction in the MDWG of a 15-year retro-
spective cohort of ELBW and VLBW infants exposed
to a higher dose and duration of caffeine for the treatment
of AOP. In their original publication, Schmidt et al. ob-
served a greater initial weight loss for premature infants
treated with caffeine during the first 3 weeks of life and
the trend gradually reduced during the following
weeks.5,6 However, in our study, the higher dose of main-
tenance oral caffeine for a prolonged period was associ-
ated with a consistent suboptimal weight gain.
Previous studies have demonstrated comparable respi-
ratory benefits from 2.5 to 5mg/kg of elemental caffeine
and thus as a general maintenance at a higher dose is ques-
tionable.6 Interestingly, one recent randomized trial sug-
gested that a twice-daily dosage is preferable and another
trial recommended that a higher dose could potentially de-
crease the extubation failure.28,29 One prospective cohort
study suggested that early commencement of caffeine re-
duced the need for invasive ventilation and incidence of
IVH.30 However, a more recent randomized trial did not
demonstrate early extubation from early caffeine initia-
tion.31 In a postauthorization European trial, routine use
of CC among premature infants was noted to produce up
to 21 specific side effects.10 Above observations suggest
that the use of caffeine among extremely premature infants
do warrant vigilance and the dose as well as the duration of
treatment should be carefully reviewed and individually
tailored.32 Our study was not aimed at analyzing the clini-
cal benefits of caffeine based on the initiation time, various
doses, or duration of treatment.
Current dosage regimens expose a 25–32-week gesta-
tion premature infant to a much higher mg/(kg$day)
dose than at any other stage in life. A maintenance dose of
5–10mg/(kg$day) of CC, often prescribed to 500–1500 g
neonates (equivalent to 150–300mg/day derived from
tea/coffee for a 60 kg woman during second trimester
of pregnancy, assuming comparable pharmacokinetics),
is higher than the high level of exposure from dietary caf-
feine sources during pregnancy quoted in the CARE
study and other recent observations.8,33 As per a recent sys-
tematic review of antenatal caffeine and impact on subop-
timal fetal weight gain, existence of a dose–response
relationship is suggestive of causation and there is no indi-
cation of a threshold effect.34 Caffeine with its psychoac-
tive properties influences the sleep cycles and the somatic
effects of this property also could modify the weight
gain.35 Caffeine typically produces prolonged sleep la-
tency, reduces the total sleep time, and worsens the sleep
quality.35
A few observations from our study with the data
spanned over a 15-year period are worth clarifying.
The average weight gain in the younger group (days
14–26) is higher (Table 1) than the group (days 28–56)
that is older and expected to be generally gaining more
weight. Following clarifications could explain our ob-
served findings: (1) many infants during 14–28 days
were still in receipt of total parenteral nutrition or partial
parenteral nutrition thus optimizing their nutritional re-
quirement and resultant better weight gain, (2) during
the first half of study period, our use of breast milk forti-
fier was suboptimal, thus affecting the weight gain more
among the 29–56 days compared with 14–28 days. As an
unexpected observation, our ventilation days (nasal and
tracheal combined) are very similar between the two
groups (Table 1). We believe that the following could
be the contributing factors: (1) The ELBW subgroup
had a relatively longer intubation and ventilation and
over 28 weeks of gestation was mainly on noninvasive
support, (2) as the cohort is over a 15-year period, signif-
icant changes in ventilation management and the resul-
tant variations in the duration of mechanical support,
(3) those infants included from the first half of the
study period perhaps had longer invasive ventilation,
(4) contribution by outliers in the 29–56-day group—
especially those with chronic lung disease (CLD).
The relative safety of caffeine compared with other
drugs used in the treatment of AOP perhaps makes clini-
cians less vigilant to limit the duration of treatment of
CC, thus leading to unnecessary prolonged exposure
with possible side effects.32 Recent advances in respira-
tory support such as nasal continuous positive pressure
with facilities for back-up breaths/synchronization,
nasal intermittent positive pressure ventilation with addi-
tional synchronization, as well as the nasal high-flow hu-
midified oxygen therapy or low-flow systems, all need
to be explored further along with postural adjustments
and/or changes to infant care procedures, to avoid
undue reliance on neonatal caffeine use. It is reassuring
to read, from their 11-year follow-up by Schmidt et al.,
Table 3. Mean Daily Weight Gain of Premature Infants Exposed to Caffeine Citrate
at Two Different Doses During Two Distinct Time Frames
Days of treatment 14–28 days p 29–56 days p
Dose of CC, mg/(kg$day) 5 10 5 10
n 248 170 214 118
MDWG, g 17.2– 12 13.0 – 10.2 0.04 15.6 – 10.8 10.2 – 9.8 0.011
MDWG, mean daily weight gain.
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that caffeine therapy for AOP did not significantly reduce
the combined rate of academic, motor, and behavioral
impairments but was associated with a reduced risk of
motor impairment.36 As per the current evidence, caf-
feine has a definite role in the management of AOP
and perhaps in the reduction of CLD, however, may
not be to the extent with which we use it liberally in
the current neonatal practice.37 Seventy years ago, intra-
muscular Brandy 0.5 cc was used in newborn infants who
failed to breathe,38 perhaps our stimulant pharmacother-
apy to manage AOP of ELBW infants could 1 day be
viewed with a similar surprise and dismay.
Audit process recommendations
Based on our observations, we have submitted recom-
mendations to the neonatal clinical guideline develop-
ment group to consider the lower dose of CC at 5mg/kg
(elemental caffeine of 2.5mg/kg) as the standard starting
maintenance dose and to appropriately incorporate addi-
tional nutritional input or consideration if ELBW and
VLBW infants are maintained on a relatively higher
dose of caffeine for prolonged periods.39 A reaudit is rec-
ommended for the audit cycle completion in 2019.
Limitations
We acknowledge the following limitations: (1) this is a
retrospective descriptive observational study and not a
randomized trial to make definitive conclusions on cau-
sality, (2) treating teams had the freedom to choose the
caffeine dose as 2.5 or 5mg/kg of elemental caffeine,
(3) there is a possibility that treating clinicians might
have chosen the higher dose for the ‘‘sicker’’ babies or
in whom they have noted persistence of apnea or low caf-
feine levels on blood tests, (4) even though both groups
were exposed to similar feeding regimens, fortifications,
and had comparable breast milk uptake, there was no
specific monitoring of the calorie or protein intake of
the two groups, (5) over the 15-year period of data collec-
tion, there were evidence-based changes to various neo-
natal guidelines and policies that could have a bearing on
the weight gain of infants, however, it is unlikely that
such confounders only affected one group over the
other, (6) we have not done a multiple logistic regression
for the statistical analysis, (7) our mean MDWG calcula-
tion was derived from thrice-weekly weight checks
rather than daily weight measurements; however, this
was reflected across both patient groups, (8) two different
CC preparations were used between the first and second
halves of the study period, however, previous studies
reported comparable clinical effects from both prepara-
tions,22 (9) observed weight trends were not correlated
with the serum concentration of caffeine in the two
groups, and (10) we excluded the initial postnatal days
when infants were on intravenous caffeine and possibly
had a relatively higher physiological weight loss. Com-
bining enteral and parenteral routes of CC in the two
study groups would have pharmacokinetic implications.
By excluding infants during the parenteral caffeine use,
perhaps we indirectly selected infants who are relatively
stable in the ‘‘growing phase’’ in both groups thus adding
more clinical relevance to our observations.
Conclusion
While a variety of dietary, ventilatory, and thermoreg-
ulatory measures are being optimized to augment postna-
tal weight gain close to the ideal intrauterine growth
curves of ELBW and VLBW infants, not paying suffi-
cient attention to one of the important catabolic agents
widely used in the neonatal units around the world is
questionable and warrants vigilance from the clinical
neonatal community. Additional nutritional supplemen-
tation while on caffeine, especially at a higher dosage
spectrum, is advisable to be incorporated to the feeding
guidelines of units using CC for prolonged periods for
the management of AOP. Our observation is neither
powered nor randomized to establish causation, howev-
er; the observed association along with the supporting
antenatal reports suggests the need for further studies
to address this underperceived element of suboptimal
postnatal weight gain among premature infants exposed
to prolonged caffeine intake.
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